Institutional dossier
The documented history of insitro: chronology, people, research, capital and compute, and governance. Every statement opens its source and its limits.
Records dated 2018 to 2026-10-30 · 0 undated
8 claims · 4 sources · 8 not editorially accepted. The counts describe this selection. They do not measure completeness or independent confirmation.
Scope, evidence and limits
Description: The company styles its name in lower case.
The records are grouped automatically. No human inspection of the selected claims, source paths or framing is recorded for this dossier. Each source passage shows how it was checked.
The dossier is computed from existing records. It is not a continuous history of the institution, and a missing record does not mean that an event or relationship did not happen. The chronology uses the dates of events and reports, not the date the public could first have known of them. Later sources can describe earlier events.
Select any statement to see its exact claim, qualification, date note, evidence passage, location in the source, source version and review status. The description above is Selekoa’s stored description of the institution, based on these sources:
Chronology
Records about the institution itself and documented changes to its frameworks, by year. Expand a year to read the claims. People’s other institutional records and related documents have their own sections. Where a date gives only the year or month, the order within it is unknown.
2018Record year · 2 claims
- insitro's purpose page, as served on 30 October 2026, states that Daphne Koller founded insitro in 2018; its Series C release of 15 March 2021 also refers to the company's "formation in 2018".insitro → is stated to have been founded in → 2018 Inspect claim & evidence ↗
Record about this institution · Stated in source · Supported
Qualification and date notes
The sources state a year only; they do not establish a legal incorporation date or a complete founder roster.
Year as stated; no month or incorporation date is given. As in the dataset's founding_stated records, no date basis is given: the date is the founding as stated, not the document date.
- insitro's purpose page, as served on 30 October 2026, states that Daphne Koller founded insitro in 2018.Daphne Koller → co-founded → insitroInspect claim & evidence ↗
Record about this institution · Stated in source · Supported
Qualification and date notes
The page names Koller as founder; the predicate records participation in founding and implies neither sole founding nor incorporation.
Founding year as stated on insitro's purpose page as served on 2026-10-30 ("founded insitro in 2018"); no month or day is given.
2020Record year · 1 claims
- insitro announced on 28 October 2020 a collaboration with Bristol Myers Squibb, stating a $50 million upfront payment, eligibility for $20 million in near-term operational milestones and up to an aggregate of more than $2 billion in discovery, development, regulatory and commercial milestones.insitro → announced a partnership with → Bristol Myers SquibbInspect claim & evidence ↗
Record about this institution · Stated in source · Supported Announced
Activity: announced
Qualification and date notes
Announced terms as insitro states them. The milestone amounts are "up to" and conditional; they are not payments, and the headline "total potential deal value" is not recorded as a value received.
Date of insitro's release.
2021Record year · 3 claims
- insitro's release of 15 March 2021 states that its Series C financing was led by Canada Pension Plan Investment Board (CPP Investments).CPP Investments → participated in funding for → insitroInspect claim & evidence ↗
Record about this institution · Stated in source · Supported
Stage: announced
Qualification and date notes
Lead participation as stated; the round total is not attributed to CPP Investments, and its contribution is not stated. The release names many other participants, not recorded individually here.
Date of the release.
- insitro announced on 15 March 2021 that it had raised $400 million in a Series C financing.insitro → announced funding of → 400000000 USDInspect claim & evidence ↗
Record about this institution · Stated in source · Supported
Stage: announced · exact USD 400,000,000 · round total
Qualification and date notes
The announced round total, not a valuation or any one investor's contribution; the release states the closing as expected, and closing is not recorded.
Date of the release; the release states that the financing was expected to close during the first full week of April 2021.
- insitro's Series C release of 15 March 2021 names Daphne Koller as founder and chief executive officer of insitro.Daphne Koller → held role at → insitroInspect claim & evidence ↗
Record about this institution · Stated in source · Supported
Qualification and date notes
A historical role snapshot; neither the start nor the end of the role is established.
The date identifies this documented announcement or publication; it does not establish a continuing state.
2024Record year · 1 claims
- insitro announced on 9 October 2024 three strategic agreements with Eli Lilly and Company on potential new medicines for metabolic diseases.insitro → announced a partnership with → Eli Lilly and CompanyInspect claim & evidence ↗
Record about this institution · Stated in source · Supported Announced
Activity: announced
Qualification and date notes
An announced arrangement; the release discloses no amounts in the passage quoted, and the record does not establish that any programme reached the clinic.
Date of insitro's release.
2026Record year · 1 claims
- insitro's purpose page, as served on 30 October 2026, refers to Daphne Koller as "Our CEO".Daphne Koller → held role at → insitroInspect claim & evidence ↗
Record about this institution · Stated in source · Supported
Qualification and date notes
A snapshot at the retrieval date; it is not a tenure.
Snapshot of the page as served on the retrieval date.